Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another study of patients treated with cetuximab, an odds ratio of 0.95 (95% CI: 0.18, 5.15; P = .95) for DFS was reported for patients with KRAS G12C; however, the comparator was not clearly defined.67”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [67]
In the citing paper
“however, the comparator was not clearly defined.67”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
Bournet, B., Muscari, F., Buscail, C., Assenat, E., Barthet, M., Hammel, P., Selves, J., Guimbaud, R., Cordelier, P., & Buscail, L. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.18 · Cited by 205
Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer
Zocche, D. M., Ramirez, C., Fontao, F. M., Costa, L. D., & Redal, M. A. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00116 · Cited by 50 · cited 1×
“therapy was significantly higher than that of patients harboring mutants.(4) Moreover, a large phase III clinical study has showed that the codons 12 and 13 of exon 2 of the KRAS gene correlate with blocked EGFR gene monoclonal antibody status with cetuximab and panitumumab and that patients with wild-type KRAS benefi…”
Background
Cited by
Strickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P. (2023) · The Oncologist · doi:10.1093/oncolo/oyad138 · Cited by 54
Metadata
- Authors
- Pang, X.-L., Li, Q.-X., Ma, Z.-P., Shi, Y., Ma, Y.-Q., Li, X.-X., Cui, W.-L., & Zhang, W.
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-05
- Volume
- Volume 10
- Pages
- 2645-2654
- ISSN
- 1178-6930
- Cited by
- 7
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation. https://app.cochat.ai/papers/10.2147/ott.s133203
- The paper
- Pang, X.-L., Li, Q.-X., Ma, Z.-P., Shi, Y., Ma, Y.-Q., Li, X.-X., Cui, W.-L., & Zhang, W. (2017). Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation. OncoTargets and Therapy. https://doi.org/10.2147/ott.s133203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.